SCHEMBL26089405

SCHEMBL26089405

O=C(O)c1ccccc1-c1cc2ccncc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.48
KDM4E B2RXH2 2/20 0.46
RAB9A P51151 1/20 0.46
DAO P14920 1/20 0.46
POLB P06746 1/20 0.44
CYP19A1 P11511 1/20 0.41
CDC7 O00311 1/20 0.41
F3 P13726 7/20 0.41
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
KDM5A P29375 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
HRH4 Q9H3N8 1/20 0.40
DHODH Q02127 1/20 0.39
CLK2 P49760 1/20 0.39
CLK3 P49761 1/20 0.39
DYRK1A Q13627 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26086683 0.89 F3 (0.50) SLC22A12KDM4ERAB9ADAOPOLB
SCHEMBL26087356 0.84 PRMT5 (0.45) SLC22A12KDM4ERAB9ADAOPOLB
SCHEMBL7062756 0.83 SLC22A12 (0.57) SLC22A12KDM4ERAB9ADAOPOLB
SCHEMBL27437769 0.82 KDR (0.56) SLC22A12KDM4ERAB9ADAOPOLB
SCHEMBL3765594 0.77 CYP19A1 (0.45) SLC22A12RAB9ADAOCYP19A1CDC7
SCHEMBL29871188 0.77 CYP19A1 (0.45) SLC22A12RAB9ADAOCYP19A1CDC7
SCHEMBL11438464 0.76 POLB (0.50) KDM4ERAB9ADAOPOLBCASP3
SCHEMBL26088542 0.76 DAO (0.43) SLC22A12KDM4EDAOCYP19A1F3
SCHEMBL6492488 0.76 CYP19A1 (0.63) KDM4ERAB9ADAOCYP19A1CDC7
SCHEMBL15270655 0.75 DAO (0.64) KDM4EDAOPOLBKDM5AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2026-03-17 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-04-27 US disclosed
EP-4110777-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) 2023-01-04 EP disclosed
CN-115175909-A Pyrrolopyridine and imidazopyridine antiviral compounds 鲁汶天主教大学 2022-10-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130598-A1 PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS SARS1, TPI1, TPMT SLC22A12 4263/4885KDM4E 3519/4885RAB9A 2809/4885
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds SARS1, TPMT, ZC3HAV1 SLC22A12 4617/4885KDM4E 612/4885RAB9A 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.